Ignite Creation Date:
2025-12-24 @ 11:41 PM
Ignite Modification Date:
2026-01-10 @ 5:45 PM
Study NCT ID:
NCT02258451
Status:
COMPLETED
Last Update Posted:
2023-11-24
First Post:
2014-09-30
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer
Sponsor:
Bayer
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-06-04
Start Date Type:
ACTUAL
Primary Completion Date:
2020-01-22
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-10-28
Completion Date Type:
ACTUAL
First Submit Date:
2014-09-30
First Submit QC Date:
None
Study First Post Date:
2014-10-07
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2022-01-17
Results First Submit QC Date:
None
Results First Post Date:
2022-03-10
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-11-22
Last Update Post Date:
2023-11-24
Last Update Post Date Type:
ACTUAL